Denosumab biosimilar by Celltrion for Osteoporosis: Likelihood of Approval

Denosumab biosimilar is under clinical development by Celltrion and currently in Phase I for Osteoporosis.

Paxlovid Fails First Test in Long COVID

A 15-day course of the antiviral nirmatrelvir-ritonavir (Paxlovid) didn’t improve symptoms of long COVID, according to a randomized controlled trial that was stopped early for

June 8, 2024

Does eating chili pepper decrease or increase obesity risk?

Researchers in Frontiers in Nutrition investigate whether eating chili pepper decreases or increases the risk of obesity in U.S. adults.

June 4, 2024

NephroDI Therapeutics, MSRD partner to develop therapy for NDI

NephroDI Therapeutics’ NDI-5001 is being developed to treat X-linked congenital nephrogenic diabetes insipidus, a rare genetic kidney condition. Credit: crystal light / Shutterstock.com. NephroDI Therapeutics

June 23, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.